GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$41.22 USD
+0.04 (0.10%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $41.20 -0.02 (-0.05%) 6:20 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$41.22 USD
+0.04 (0.10%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $41.20 -0.02 (-0.05%) 6:20 PM ET
3-Hold of 5 3
A Value C Growth B Momentum B VGM
Zacks News
Gilead (GILD) Q2 Earnings Beat Estimates, HIV Sales Decline
by Zacks Equity Research
Gilead (GILD) beats on sales and earnings in the second quarter. While the HIV business lags due to generic competition, Veklury maintains momentum.
Pharma Stock Roundup: Q2 Earnings of MRK, PFE & Others, FDA Approvals for GSK, ABBV
by Kinjel Shah
Pfizer (PFE), Merck (MRK) and others announce Q2 results. FDA approves AbbVie's (ABBV) new antibiotic injection and expands use of Merck's Keytruda and Glaxo's Shingrix and Nucala.
Sanofi (SNY) Q2 Earnings & Sales Beat, 2021 EPS View Raised
by Zacks Equity Research
Sanofi (SNY) earnings and sales beat estimates in the second quarter of 2021. Dupixent and vaccines drive sales growth in the reported quarter.
Glaxo's (GSK) Q2 Earnings Beat, Revenues on Recovery Track
by Zacks Equity Research
Glaxo's (GSK) revenues benefit from recovery in sales of products across all segments and additional revenues from the supply of pandemic adjuvant to partners.
Glaxo (GSK) Beats Earnings and Revenues Estimates in Q2
by Zacks Equity Research
Glaxo (GSK) beats earnings as well as revenues estimates in the second quarter of 2021. Stock up.
Drug/Biotech Stock Earnings on Jul 28: PFE, GSK, BMY, BMRN & TLRY
by Zacks Equity Research
Let us take a look at five drug/biotech companies - PFE, GSK, BMY, BMRN and TLRY - which are gearing up for their earnings release.
Glaxo (GSK) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Glaxo's (GSK) newer respiratory and HIV drugs are likely to have driven second-quarter sales. However, sales of vaccines are likely to have been hurt by COVID-19 vaccine prioritization.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, PFE, ABBV, LLY & MRK FDA Updates
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) announce Q2 results. FDA delays decisions on JAK inhibitor drugs of Lilly (LLY), AbbVie (ABBV) and Pfizer (PFE) for eczema indication.
Regeneron's (REGN) Antibody Cocktail for COVID-19 Approved in Japan
by Zacks Equity Research
Regeneron's(REGN) cocktail for the treatment of COVID-19 gets approval in Japan as Ronapreve.
Merck (MRK) Gets FDA Nod for Pneumococcal Vaccine Vaxneuvance
by Zacks Equity Research
Merck's (MRK) 15-valent pneumococcal conjugate vaccine, Vaxneuvance includes pneumococcal serotypes, 22F and 33F, which are not included in the currently licensed 13-valent conjugate vaccines.
Will J&J (JNJ) Initiate Pharma Q2 Earnings With a Beat?
by Zacks Equity Research
J&J's (JNJ) Pharma segment is expected to have performed above market. Market recovery might have led to continued recovery in Medical Devices segment in the second quarter.
Vir Biotech (VIR) Begins Dosing in Phase II Hepatitis B Study
by Zacks Equity Research
Vir Biotechnology (VIR) doses the first patient in a phase II study evaluating the combo of VIR-2218 plus VIR-3434 for treating patients with chronic hepatitis B virus infection.
Lilly (LLY) Stock Riding on Pipeline Developments This Year
by Zacks Equity Research
Lilly's (LLY) shares are up this year mainly due to positive developments related to its interesting pipeline of cancer, diabetes and Alzheimer's candidates.
Pharma Stock Roundup: GSK's New Deal With Alector, MRK & AZN's FDA Updates
by Kinjel Shah
Glaxo (GSK) to co-develop Alector's two candidates for neurodegenerative diseases. FDA updates for Merck (MRK) and AstraZeneca (AZN)
Amgen (AMGN)/AstraZeneca's Asthma Drug Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Amgen (AMGN)/AstraZeneca's BLA for tezepelumab for the treatment of asthma.
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More
by Zacks Equity Research
The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).
Merck's (MRK) Keytruda Gets FDA Nod for Advanced Skin Cancer
by Zacks Equity Research
Merck (MRK) gets approval from the FDA for the label expansion of Keytruda as a monotherapy for treating patients with locally advanced cutaneous squamous cell carcinoma.
Alector (ALEC) Up on Tie-Up With Glaxo for Neurological Diseases
by Zacks Equity Research
Alector (ALEC) signs a global collaboration deal with Glaxo to co-develop/commercialize two monoclonal antibodies - AL001 and AL101 ¿¿¿ for treating various neurodegenerative diseases. Stock up.
Glaxo (GSK)/Alector Ink Deal for Neurodegenerative Indications
by Zacks Equity Research
Glaxo (GSK) and Alector set to co-develop and co-commercialize AL001 and AL101 for neurodegenerative diseases. Glaxo issues a formal response to activist hedge investor, Elliott's call for board changes.
Merck (MRK) to Withdraw a Gastric Cancer Indication for Keytruda
by Zacks Equity Research
Merck's (MRK) Keytruda is approved under FDA's accelerated pathway for recurrent gastric or gastroesophageal junction adenocarcinoma indication but fails in post-marketing commitment study.
CureVac (CVAC) Announces Final Analysis of its COVID-19 Vaccine Study
by Zacks Equity Research
CureVac (CVAC) announces final analysis from its HERALD study on CVnCoV showing efficacy of 48%.
3 Big Drugmakers Likely to be in Focus in Second Half of 2021
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Bayer (BAYRY) are three large drug sector companies worth buying and holding for the next few months and beyond.
Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU (Revised)
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study
Merck's (MRK) Keytruda Gets Nod for Esophageal Cancer in EU
by Zacks Equity Research
Merck's (MRK) Keytruda gets approval in combination with chemotherapy in first-line setting for advanced esophageal and HER2-negative GEJ cancer based on data from the phase III KEYNOTE-590 study
Pfizer (PFE) Begins Dosing in Prostate Cancer Drugs Study
by Zacks Equity Research
Pfizer (PFE) is developing its oral PARP inhibitor, talazoparib (Talzenna), in combination with Xtandi as a potential treatment for castration-sensitive prostate cancer in a late-stage study.